Citeline Podcasts Citeline

Audio roundup of selected biopharma industry content from Scrip over the business week ended 31 May 2024. In this episode: ASCO preview; Asahi’s US acquisition; Novartis aims for renal disease dominance; paying for gene therapies; and US BIOSECURE Act diluted.

https://scrip.citeline.com/SC150361/Quick-Listen-Scrips-Five-MustKnow-Things

Playlist: https://soundcloud.com/citelinesounds/sets/scrips-five-must-know-things

An interview with Genmab’s Jan van de Winkel to mark 25 years of the company, and 20 years of the Scrip Awards. A brief history of the antibody-focused biotech company so far, and its plans for future expansion.

In this episode we unpack the Corporate Sustainability Reporting Directive (CSRD) with the help of ESG expert Jasper Crone, drilling down into exactly what consumer healthcare companies need to know about this enormously complex and significant piece of EU legislation.


3:30 Introduction to the CSRD
7:45 What companies are affected by the CSRD
15:00 Specific implications for consumer health companies
21:00 Getting materiality right
25:00 CSRD to do list
32:00 Who’s afraid of targets?
37:00 Who’s responsible for CSRD in companies?
39:00 CSRD and the EU Green Deal
45:00 How will CSRD shape the way companies operate?

Advancing Investigational New Drugs (INDs) can be a complex process, especially for smaller companies. Listen to your free podcast now as Marcus Delatte, PhD, Vice President at Allucent and Harshini Neelakantan, Executive Director at Ridgeline Therapeutics discuss best practices and considerations for leveraging your pre-IND meeting and submitting a successful IND application.

Listen now for insights into:

• Current trends and challenges related to IND submissions
• The purpose and benefits of pre-IND meetings with regulatory bodies
• Indicators that should prompt companies to request a pre-IND meeting
• The role of consultants in supporting sponsors in pre-IND meetings
• Getting the most from your pre-IND meeting and tips for IND application success
• How IND submissions will evolve in the future

Astellas Pharma’s chief commercial officer, Claus Zieler, discusses the biopharma industry’s responsibility to drive change in health care.

NeuShen CEO Joan Shen discusses with Brian Yang about developing CNS drugs in China, the venture's business rationale, challenges and fundraising. She also discusses two leading assets for schizophrenia and epilepsy in first-in-human studies, as well as a gene therapy collaboration for ALS with UMass's Gao Lab.
https://scrip.citeline.com/SC150328/China-Biotech-CEO-Interview-Starting-A-CNS-Venture-In-An-Economic-Downturn
Playlist: https://on.soundcloud.com/AaFyPUxfD2RiDEis5